PLUS1
12.18
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Adverum Biotechnologies Inc | ADVM | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.00 | 0.0% | 12.18 | 07:00:32 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 12.18 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 11.77 | 12.87 | 1.10 | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 12.18 | USD |
Adverum Biotechnologies Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.19B | 97.33M | 89.69M | $ 250.00k | $ - | -1.01 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Adverum Biotechnologies News
| Date | Time | Source | News Article |
|---|---|---|---|
| 10/20/2020 | 09:00 | GlobeNewswire Inc. | Adverum Biotechnologies to Present New Data from the OPTIC.. |
| 9/15/2020 | 08:00 | GlobeNewswire Inc. | Adverum Biotechnologies Announces Appointment of Christopher.. |
| 9/10/2020 | 08:00 | GlobeNewswire Inc. | Adverum Biotechnologies to Participate in the Cantor Virtual.. |
| 8/20/2020 | 14:22 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) |
| 8/19/2020 | 18:48 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 8/19/2020 | 18:46 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 8/18/2020 | 09:00 | GlobeNewswire Inc. | Adverum Biotechnologies Announces Closing of $217.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADVM Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 11.70 | 12.58 | 11.28 | 12.07 | 660,099 | 0.48 | 4.1% |
| 1 Month | 10.44 | 12.58 | 9.83 | 11.29 | 801,017 | 1.74 | 16.67% |
| 3 Months | 17.91 | 19.3599 | 9.83 | 12.42 | 1,154,620 | -5.73 | -31.99% |
| 6 Months | 13.39 | 26.98 | 9.83 | 16.46 | 1,202,340 | -1.21 | -9.04% |
| 1 Year | 7.45 | 26.98 | 6.58 | 13.76 | 1,243,035 | 4.73 | 63.49% |
| 3 Years | 3.15 | 26.98 | 2.62 | 9.79 | 1,011,831 | 9.03 | 286.67% |
| 5 Years | 8.00 | 26.98 | 2.40 | 8.99 | 712,042 | 4.18 | 52.25% |
Adverum Biotechnologies Description
| Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. The company is committed to discovering and developing novel medicines that can offer potentially life-changing therapeutic benefit to patients living with rare diseases or diseases of the eye, who currently have limited or burdensome treatment options. Its services are focused on advancing three lead gene therapy programs to address unmet needs in wet age-related macular degeneration and in rare diseases alpha-1 antitrypsin deficiency and hereditary angioedema. Its leading programs include ADVM-022, ADVM-043 and ADVM-053. |
